Inhibition of amyloid-β aggregation in Alzheimer's disease

Current Pharmaceutical Design

Volumn 20, Issue 8, 2014, Pages 1223-1243

  Wang, Qiuming ^a   Yu, Xiang ^a   Li, Lingyan ^a   Zheng, Jie ^a  

^a The University of Akron   (United States)

Author keywords

Alzheimer disease; Amyloid inhibitor; Amyloid toxicity; Amyloid beta; Protein aggregation

Indexed keywords

2,9 DIMETHYL 1,10 PHENANTHROLINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN INHIBITOR; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APIGENIN; APOMORPHINE; AZURE C; CONGO RED; CURCUMIN; CYCLIC PEPTIDE INHIBITOR; DAUNORUBICIN; HEMATIN; HEMIN; INDOMETACIN; JUGLONE; MEPACRINE MUSTARD; NANOPARTICLE; NORDIHYDROGUAIARETIC ACID; PERPHENAZINE; PHENOLSULFONPHTHALEIN; POLYPHENOL DERIVATIVE; PROTEIN INHIBITOR; RHODAMINE B; RIFAMYCIN; ROLITETRACYCLINE; RS 0466; THIOFLAVINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; BIOLOGICAL PRODUCT; MOLECULAR LIBRARY; PEPTIDE FRAGMENT; PROTEIN BINDING;

ALZHEIMER DISEASE; AMYLOID PLAQUE; BETA SHEET; COMPUTER MODEL; CYTOTOXICITY; DRUG DESIGN; DRUG DEVELOPMENT; DRUG STRUCTURE; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DOCKING; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN POLYMERIZATION; PROTEIN STRUCTURE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM; MOLECULAR LIBRARY; PATHOLOGY; PHARMACOLOGY; PROTEIN AGGREGATION, PATHOLOGICAL; THERAPEUTIC USE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL PRODUCTS; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; NANOPARTICLES; PEPTIDE FRAGMENTS; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN BINDING; SMALL MOLECULE LIBRARIES;

EID: 84903713725     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990068     Document Type: Review

References (160)

1. Rochet JC, Lansbury PT. Amyloid fibrillogenesis: themes and variations. Curr Opin Struct Biol 2000; 10: 60-68.
2. Dobson CM. Principles of protein folding, misfolding and aggregation. Seminars Cell Developmental Biol 2004; 15: 3-16.
3. Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 2006; 75: 333-66.
4. Dobson CM. Protein misfolding, evolution and disease. Trends Biochemical Sci 1999; 24: 329-32.
5. Nelson R, Eisenberg D. Structural models of amyloid-like fibrils. In: ed. eds., Adv Prot Chem Academic Press 2006; pp. 235-82.
6. Jimenez JL, Guijarro JI, Orlova E, et al. Cryo-electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing. EMBO J 1999; 18: 815-21.
7. Sawaya MR, Sambashivan S, Nelson R, et al. Atomic structures of amyloid cross-[beta] spines reveal varied steric zippers. Nature 2007; 447: 453-457.
8. Tycko R. Solid-state NMR as a probe of amyloid fibril structure. Curr Opin Chem Biol 2000; 4: 500-6.
9. Bucciantini M, Calloni G, Chiti F, et al. Prefibrillar amyloid protein aggregates share common features of cytotoxicity. J Biol Chem 2004; 279: 31374-82.
10. Dobson CM. Protein aggregation and its consequences for human disease. Protein Peptide Letters 2006; 13: 219-27.
11. Kayed R, Head E, Thompson JL, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300: 486-9.
12. Meredith SC. Protein denaturation and aggregation. cellular responses to denatured and aggregated proteins. Ann New York Acad. Sci 2006; 1066: 181-221.
13. Butterfield SM, Lashuel HA. Amyloidogenic protein-membrane interactions: mechanistic insight from model systems. Angew. Chem Int Ed 2010; 49: 5628-54.
14. Stefani M. Biochemical and biophysical features of both oligomer/fibril and cell membrane in amyloid cytotoxicity. FEBS J 2010; 277: 4602-13.
15. Jang H, Zheng J, Lal R, Nussinov R. New structures help the modeling of toxic amyloid-[beta] ion channels. Trends Biochem Sci 2008; 33: 91-100.
16. Sakono M, Zako T. Amyloid oligomers: formation and toxicity of A[1] oligomers. FEBS J 2010; 277: 1348-58.
17. Chen F-Y, Lee M-T, Huang HW. Evidence for membrane thinning effect as the mechanism for peptide-induced pore formation. Biophys J 2003; 84: 3751-8.
18. Quist A, Doudevski I, Lin H, et al. Amyloid ion channels: A common structural link for protein-misfolding disease. PNAS 2005; 102: 10427-32.
19. Wolfe MS. Secretase targets for Alzheimer's disease:[1] identification and therapeutic potential. J Med Chem 2001; 44: 2039-60.
20. Oehlrich D, Berthelot DJC, Gijsen HJM. γ-secretase modulators as potential disease modifying anti-Alzheimer's drugs. J Med Chem 2010; 54: 669-98.
21. Takahashi T, Mihara H. Peptide and protein mimetics inhibiting amyloid-peptide aggregation. Acc Chem Res 2008; 41: 1309-18.
22. Hamaguchi T, Ono K, Yamada M. Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer's disease. Cellular Mol Life Sci 2006; 63: 1538-52.
23. Meng F, Raleigh DP, Abedini A. Combination of kinetically selected inhibitors in trans leads to highly effective inhibition of amyloid formation. J Am Chem Soc 2010; 132: 14340-2.
24. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003; 39: 889-909.
25. Hardy J, Duff K, Gwinn Hardy K, Perez-Tur J, Hutton M. Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau. Nature Neurosci 1998; 1: 355-8.
26. Maji SK, Perrin MH, Sawaya MR, et al. Functional amyloids as natural storage of peptide hormones in pituitary secretory granules. Science 2009; 325: 328-32.
27. Kang DY, Lee JH, Oh BK, Choi JW. Ultra-sensitive immunosensor for [beta]-amyloid (1-42) using scanning tunneling microscopybased electrical detection. Biosensors and Bioelectronics 2009; 24: 1431-6.
28. Monge-Argilés J, Muñoz-Ruiz C, Pampliega-Pérez A, et al. Biomarkers of Alzheimer's disease in the cerebrospinal fluid of spanish patients with mild cognitive impairment. Neurochemical Res 2011; 36: 986-93.
29. De Felice FG, Ferreira ST. β-amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease. Cellular Mol Neurobiol 2002; 22: 545-63.
30. Dash PK, Moore AN, Orsi SA. Blockade of [gamma]-secretase activity within the hippocampus enhances long-term memory. Biochem Biophys Res Commun 2005; 338: 777-82.
31. Asai M, Hattori C, Iwata N, et al. The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice. J Neurochem 2006; 96: 533-40.
32. Bacskai BJ, Kajdasz ST, Christie RH, et al. Imaging of amyloid-[beta] deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 2001; 7: 369-72.
33. Bartolini M, Andrisano V. Strategies for the Inhibition of Protein Aggregation in Human Diseases. ChemBioChem 2010; 11: 1018-35.
34. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. J Neurochem 2003; 87: 172-81.
35. Davis TJ, Soto-Ortega DD, Kotarek JA, et al. Comparative study of inhibition at multiple stages of amyloid-beta self-assembly provides mechanistic insight. Mol Pharmacol 2009; 76: 405-13.
36. Findeis MA. Approaches to discovery and characterization of inhibitors of amyloid-peptide polymerization. BBA-Molecular Basis of Disease 2000; 1502: 76-84.
37. Necula M, Kayed R, Milton S, Glabe CG. Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J Biol Chem 2007; 282: 10311-24.
38. Feng BY, Toyama BH, Wille H, et al. Small-molecule aggregates inhibit amyloid polymerization. Nat Chem Biol 2008; 4: 197-9.
39. Abelein A, Bolognesi B, Dobson CM, Gräslund A, Lendel C. Hydrophobicity and conformational change as mechanistic determinants for nonspecific modulators of amyloid-β selfassembly. Biochemistry 2011; 51: 126-37.
40. Maezawa I, Hong HS, Liu R, et al. Congo red and thioflavin-T analogs detect A oligomers. J Neurochem 2008; 104: 457-68.
41. Ehrnhoefer DE, Bieschke J, Boeddrich A, et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nature Struct Mol Biol 2008; 15: 558-66.
42. McKee AC, Carreras I, Hossain L, et al. Ibuprofen reduces A[beta], hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res 2008; 1207: 225-36.
43. Van Dam D, Coen K, De Deyn PP. Ibuprofen modifies cognitive disease progression in an Alzheimer's mouse model. J Psychopharmacol 2008: 0269881108097630.
44. Yang F, Lim GP, Begum AN, et al. Curcumin inhibits formation of amyloid oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005; 280: 5892-901.
45. Ritchie CW, Bush AI, Mackinnon A, et al. Metal-protein attenuation with Iodochlorhydroxyquin (Clioquinol) targeting A{beta} amyloid deposition and toxicity in Alzheimer disease: A pilot phase 2 clinical trial. Arch Neurol 2003; 60: 1685-91.
46. Yamin G, Ruchala P, Teplow DB. A peptide hairpin inhibitor of amyloid beta-protein oligomerization and fibrillogenesis. Biochemistry 2009; 48: 11329-31.
47. Soto P, Griffin MA, Shea JE. New insights into the mechanism of alzheimer amyloid-{beta} fibrillogenesis inhibition by n-Methylated peptides. Biophys J 2007; 93: 3015-25.
48. Sciarretta KL, Boire A, Gordon DJ, Meredith SC. Spatial separation of [beta]-sheet domains of [beta]-amyloid: disruption of each [beta]-sheet by N-methyl amino acids. Biochemistry 2006; 45: 9485-95.
49. Lendel C, Bertoncini CW, Cremades N, et al. On the mechanism of nonspecific inhibitors of protein aggregation: dissecting the interactions of [1]-synuclein with congo red and lacmoid. Biochemistry 2009; 48: 8322-34.
50. Cheng B, Liu X, Gong H, et al. Coffee components inhibit amyloid formation of human islet amyloid polypeptide in vitro: possible link between coffee consumption and diabetes mellitus. J Agricultural Food Chem 2011; 59: 13147-55.
51. Porat Y, Abramowitz A, Gazit E. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des 2006; 67: 27-37.
52. Bulic B, Pickhardt M, Mandelkow E-M, Mandelkow E. Tau protein and tau aggregation inhibitors. Neuropharmacology 2010; 59: 276-89.
53. Ding Q, Dimayuga E, Keller JN. Oxidative damage, protein synthesis, and protein degradation in alzheimers disease. Curr Alzheimer Res 2007; 4: 73-9.
54. Ono K, Hirohata M, Yamada M. Ferulic acid destabilizes preformed-amyloid fibrils in vitro. Biochemical Biophys Res Comm 2005; 336: 444-9.
55. Yan JJ, Cho JY, Kim HS, et al. Protection against-amyloid peptide toxicity in vivo with long-term administration of ferulic acid. Br J Pharmacol 2001; 133: 89-96.
56. Sultana R, Ravagna A, Mohmmad-Abdul H, Calabrese V, Butterfield DA. Ferulic acid ethyl ester protects neurons against amyloid β-peptide(1-42)-induced oxidative stress and neurotoxicity: relationship to antioxidant activity. J Neurochem 2005; 92: 749-58.
57. Ono K, Hasegawa K, Yoshiike Y, Takashima A, Yamada M, Naiki H. Nordihydroguaiaretic acid potently breaks down pre-formed Alzheimer's β-amyloid fibrils in vitro. J Neurochem 2002; 81: 434-40.
58. Ono K, Hasegawa K, Yamada M, Naiki H. Nicotine breaks down preformed Alzheimer's β-amyloid fibrils in vitro. Biological Psychiatry 2002; 52: 880-6.
59. Ono K, Hasegawa K, Naiki H, Yamada M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J Neurosci Res 2004; 75: 742-50.
60. Zheng J, Ma B, Nussinov R. Consensus features in amyloid fibrils: sheet-sheet recognition via a (polar or nonpolar) zipper structure. Physical Biology 2006; 3: P1-P4.
61. Potter KJ, Scrocchi LA, Warnock GL, et al. Amyloid inhibitors enhance survival of cultured human islets. Biochimica et Biophysica Acta (BBA)-General Subjects 2009; 1790: 566-74.
62. Sciarretta KL, Gordon DJ, Meredith SC. Peptide-based inhibitors of amyloid assembly. In: Indu K, Ronald W, ed.^eds., Methods in Enzymology. Academic Press 2006; pp. 273-312.
63. Sgourakis NG, Yan Y, McCallum SA, Wang C, Garcia AE. The Alzheimer's peptides A[beta]40 and 42 adopt distinct conformations in water: a combined MD/NMR study. J Mol Biol 2007; 368: 1448-57.
64. Chimon S, Ishii Y. Capturing intermediate structures of alzheimer's beta-amyloid, Abeta(1-40), by solid-state NMR spectroscopy. J Am Chem Soc 2005; 127: 13472-3.
65. Olofsson A, Sauer-Eriksson AE, Ohman A. The solvent protection of alzheimer amyloid-beta-(1-42) fibrils as determined by solution NMR spectroscopy. J Biol Chem 2006; 281: 477-83.
66. Fradinger EA, Monien BH, Urbanc B, et al. C-terminal peptides coassemble into Abeta42 oligomers and protect neurons against Abeta42-induced neurotoxicity. Proc Natl Acad Sci USA 2008; 105: 14175-80.
67. Hilbich C, Kisters-Woike B, Reed J, Masters CL, Beyreuther K. Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease βA4 peptides. J Mol Biol 1992; 228: 460-73.
68. Soto C, Kindy MS, Baumann M, Frangione B. Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. Biochem Biophys Res Commun. 1996; 226: 672-80.
69. Tjernberg LO, Näslund J, Lindqvist F, et al. Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J Biol Chem 1996; 271: 8545-8.
70. Chen Z, Krause G, Reif B. Structure and Orientation of Peptide Inhibitors Bound to Beta-amyloid Fibrils. J Mol Biol 2005; 354: 760-76.
71. Gordon DJ, Tappe R, Meredith SC. Design and characterization of a membrane permeable N-methyl amino acid-containing peptide that inhibits Abeta1-40 fibrillogenesis. J Peptide Res 2002; 60: 37-55.
72. Gordon DJ, Sciarretta KL, Meredith SC. Inhibition of β-Amyloid(40) fibrillogenesis and disassembly of β-Amyloid(40) fibrils by short β-Amyloid congeners containing N-methyl amino acids at alternate residues. Biochemistry 2001; 40: 8237-45.
73. Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castaño EM, Frangione B. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nature Med 1998; 4: 822-6.
74. Fradinger EA, Monien BH, Urbanc B, et al. C-terminal peptides coassemble into A[1]42 oligomers and protect neurons against Aβ42-induced neurotoxicity. PNAS 2008; 105: 14175-80.
75. Cairo CW, Strzelec A, Murphy RM, Kiessling LL. Affinity-based inhibition of [1]-amyloid toxicity. Biochemistry 2002; 41: 8620-9.
76. Walsh DM, Townsend M, Podlisny MB, et al. Certain inhibitors of synthetic amyloid β-peptide (Aβ) fibrillogenesis block oligomerization of natural Aβ and thereby rescue long-term potentiation. J Neurosci 2005; 25: 2455-62.
77. Austen BM, Paleologou KE, Ali SAE, Qureshi MM, Allsop D, El-Agnaf OMA. Designing peptide inhibitors for oligomerization and toxicity of alzheimer's β-amyloid peptide. Biochemistry 2008; 47: 1984-92.
78. Yan LM, Velkova A, Tatarek-Nossol M, Andreetto E, Kapurniotu A. IAPP mimic blocks Aβ cytotoxic self-assembly: crosssuppression of amyloid toxicity of Aβ and IAPP suggests a molecular link between Alzheimer's disease and type II diabetes. Ange Chem Inter Ed 2007; 46: 1246-52.
79. Yan LM, Tatarek-Nossol M, Velkova A, Kazantzis A, Kapurniotu A. Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesis. Proc Natl Acad Sci USA 2006; 103: 2046-51.
80. Rezaei-Ghaleh N, Andreetto E, Yan LM, Kapurniotu A, Zweckstetter M. Interaction between amyloid beta peptide and an aggregation blocker peptide mimicking islet amyloid polypeptide. PLoS ONE 2011; 6: e20289.
81. Glabe CG. Conformation-dependent antibodies target diseases of protein misfolding. Trends Biochem Sci 2004; 29: 542-7.
82. Nicolls MR. The Clinical and Biological Relationship between Type II Diabetes Mellitus and Alzheimers Disease. Curr Alzheimer Res 2004; 1: 47-54.
83. Kreuter J, Shamenkov D, Petrov V, et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target 2002; 10: 317-25.
84. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001; 47: 65-81.
85. Roney C, Kulkarni P, Arora V, et al. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. J Control Release 2005; 108: 193-214.
86. Fei L, Perrett S. Effect of nanoparticles on protein folding and fibrillogenesis. Int J Mol Sci 2009; 10: 646-55.
87. Murphy CJ, Gole AM, Stone JW, et al. Gold nanoparticles in biology: beyond toxicity to cellular imaging. Acc Chem Res 2008; 41: 1721-30.
88. Connor EE, Mwamuka J, Gole A, Murphy CJ, Wyatt MD. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small 2005; 1: 325-7.
89. Mihyun Lim DS-O, Rahina Mahtab, and Melissa A. Moss. Gold Nanospheres as Inhibitors of Amyloid-β Protein Aggregation Involved in Alzheimer's Disease. J South Carolina Acad Sci 2011; 9: 14.
90. Kogan MJ, Bastus NG, Amigo R, et al. Nanoparticle-mediated local and remote manipulation of protein aggregation. Nano Letters 2006; 6: 110-5.
91. Bastus NG, Kogan MJ, Amigo R, et al. Gold nanoparticles for selective and remote heating of beta-amyloid protein aggregates. Materials Sci Engineering C-Biomimetic Supramolecular Systems 2007; 27: 1236-40.
92. Olmedo I, Araya E, Sanz F, et al. How changes in the sequence of the peptide CLPFFD-NH2 can modify the conjugation and stability of gold nanoparticles and their affinity for beta-amyloid fibrils. Bioconjug Chem 2008; 19: 1154-63.
93. Araya E, Olmedo I, Bastus NG, Guerrero S, Puntes VF, Giralt E, Kogan MJ. Gold Nanoparticles and Microwave Irradiation Inhibit Beta-Amyloid Amyloidogenesis. Nanoscale Res Letters 2008; 3: 435-43.
94. Yoo SI, Yang M, Brender JR, et al. Inhibition of Amyloid Peptide Fibrillation by Inorganic Nanoparticles: Functional Similarities with Proteins. Angewandte Chemie-Int Edition 2011; 50: 5110-5.
95. Kim JE, Lee M. Fullerene inhibits beta-amyloid peptide aggregation. Biochem Biophys Res Commun 2003; 303: 576-9.
96. Pai AS, Rubinstein I, Onyuksel H. PEGylated phospholipid nanomicelles interact with beta-amyloid((1-42)) and mitigate its beta-sheet formation, aggregation and neurotoxicity in vitro. Peptides 2006; 27: 2858-66.
97. Cabaleiro-Lago C, Quinlan-Pluck F, Lynch I, et al. Inhibition of amyloid beta protein fibrillation by polymeric nanoparticles. J Am Chem Soc 2008; 130: 15437-43.
98. Xiao L, Zhao D, Chan WH, Choi MM, Li HW. Inhibition of beta 1-40 amyloid fibrillation with N-acetyl-L-cysteine capped quantum dots. Biomaterials 2010; 31: 91-8.
99. Akiyoshi K, Sasaki Y, Sunamoto J. Molecular chaperone-like activity of hydrogel nanoparticles of hydrophobized pullulan: thermal stabilization with refolding of carbonic anhydrase B. Bioconjug Chem 1999; 10: 321-4.
100. Nomura Y, Sasaki Y, Takagi M, Narita T, Aoyama Y, Akiyoshi K. Thermoresponsive controlled association of protein with a dynamic nanogel of hydrophobized polysaccharide and cyclodextrin: heat shock protein-like activity of artificial molecular chaperone. Biomacromolecules 2005; 6: 447-52.
101. Ikeda K, Okada T, Sawada S, Akiyoshi K, Matsuzaki K. Inhibition of the formation of amyloid beta-protein fibrils using biocompatible nanogels as artificial chaperones. FEBS Lett 2006; 580: 6587-95.
102. Rocha S, Thunemann AF, Pereira Mdo C, Coelho M, Mohwald H, Brezesinski G. Influence of fluorinated and hydrogenated nanoparticles on the structure and fibrillogenesis of amyloid betapeptide. Biophys Chem 2008; 137: 35-42.
103. Liu G, Men P, Harris PL, Rolston RK, Perry G, Smith MA. Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci Lett 2006; 406: 189-93.
104. Liu G, Men P, Kudo W, Perry G, Smith MA. Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease. Neurosci Lett 2009; 455: 187-90.
105. Cui Z, Lockman PR, Atwood CS, et al. Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases. Eur J Pharm Biopharm 2005; 59: 263-72.
106. Dykes GM. Dendrimers: a review of their appeal and applications. J Chem Technol Biotechnol 2001; 76: 903-18.
107. Miura Y, Onogi S, Fukuda T. Syntheses of sulfo-glycodendrimers using click chemistry and their biological evaluation. Molecules 2012; 17: 11877-96.
108. Klajnert B, Cortijo-Arellano M, Cladera J, Bryszewska M. Influence of dendrimer's structure on its activity against amyloid fibril formation. Biochem Biophys Res Commun 2006; 345: 21-8.
109. Klementieva O, Benseny-Cases N, Gella A, Appelhans D, Voit B, Cladera J. Dense Shell Glycodendrimers as Potential Nontoxic Anti-amyloidogenic Agents in Alzheimer's Disease. Amyloid-Dendrimer Aggregates Morphology and Cell Toxicity. Biomacromolecules 2011; 12: 3903-9.
110. Chafekar SM, Malda H, Merkx M, et al. Branched KLVFF tetramers strongly potentiate inhibition of beta-amyloid aggregation. Chembiochem 2007; 8: 1857-64.
111. Klajnert B, Wasiak T, Ionov M, et al. Dendrimers reduce toxicity of Abeta 1-28 peptide during aggregation and accelerate fibril formation. Nanomedicine 2012; 8: 1372-8.
112. Baine M, Georgie DS, Shiferraw EZ, Nguyen TPT, Nogaj LA, Moffet DA. Inhibition of Aβ42 aggregation using peptides selected from combinatorial libraries. J Peptide Sci 2009; 15: 499-503.
113. Hong HS, Maezawa I, Budamagunta M, et al. Candidate anti-Aβ fluorene compounds selected from analogs of amyloid imaging agents. Neurobiol Aging 2010; 31: 1690-9.
114. West MW, Wang W, Patterson J, Mancias JD, Beasley JR, Hecht MH. De novo amyloid proteins from designed combinatorial libraries. Proc Natl Acad Sci USA 1999; 96: 11211-6.
115. Wang W, Hecht MH. Rationally designed mutations convert de novo amyloid-like fibrils into monomeric β-sheet proteins. Proc Natl Acad Sci USA 2002; 99: 2760-5.
116. Kim W, Kim Y, Min J, Kim DJ, Chang YT, Hecht MH. A highthroughput screen for compounds that inhibit aggregation of the Alzheimer's peptide. ACS Chemical Biol 2006; 1: 461-9.
117. Goldschmidt L, Teng PK, Riek R, Eisenberg D. Identifying the amylome, proteins capable of forming amyloid-like fibrils. PNAS 2010; 107: 3487-92.
118. Takeda T, Kumar R, Raman EP, Klimov DK. Nonsteroidal antiinflammatory drug naproxen destabilizes Aβ amyloid fibrils: a molecular dynamics investigation. J Phys Chem B 2010; 114: 15394-402.
119. Takeda T, Chang WE, Raman EP, Klimov DK. Binding of nonsteroidal anti-inflammatory drugs to Aβ fibril. Proteins: Structure, Function, and Bioinformatics 2010; 78: 2849-60.
120. Wu C, Bowers Michael T, Shea JE. On the origin of the stronger binding of PIB over thioflavin T to protofibrils of the Alzheimer amyloid-β peptide: a molecular dynamics study. Biophysical J 2011; 100: 1316-24.
121. Chen D, Martin ZS, Soto C, Schein CH. Computational selection of inhibitors of A[beta] aggregation and neuronal toxicity. Bioorg Med Chem 2009; 17: 5189-97.
122. Chini MG, Scrima M, D'Ursi AM, Bifulco G. Fibril aggregation inhibitory activity of the β-sheet breaker peptides: a molecular docking approach. J Pept Sci 2009; 15: 229-34.
123. Chang WE, Takeda T, Raman EP, Klimov DK. Molecular dynamics simulations of anti-aggregation effect of ibuprofen. Biophys J 2010; 98: 2662-70.
124. Tomaselli S, Esposito V, Vangone P, et al. The alpha-to-beta Conformational Transition of Alzheimer's Abeta-(1-42) Peptide in Aqueous Media is Reversible: A Step by Step Conformational Analysis Suggests the Location of beta Conformation Seeding. ChemBioChem 2006; 7: 257-67.
125. Bruce NJ, Chen D, Dastidar SG, Marks GE, Schein CH, Bryce RA. Molecular dynamics simulations of Aβ fibril interactions with β-sheet breaker peptides. Peptides 2010; 31: 2100-8.
126. Hetenyi C, Kortvelyesi T, Penke B. Mapping of possible binding sequences of two beta-sheet breaker peptides on beta amyloid peptide of Alzheimer's disease. Bioorg Med Chem 2002; 10: 1587-93.
127. Li J, Liu R, Lam KS, Jin L-W, Duan Y. Alzheimer's disease drug candidates stabilize A[1] protein native structure by interacting with the hydrophobic core. Biophysical J 2011; 100: 1076-82.
128. Esteras-Chopo A, Morra G, Moroni E, Serrano L, Lopez de la Paz M, Colombo G. A molecular dynamics study of the interaction of D-peptide amyloid inhibitors with their target sequence reveals a potential inhibitory pharmacophore conformation. J Mol Biol 2008; 383: 266-80.
129. Makabe K, McElheny D, Tereshko V, et al. Atomic structures of peptide self-assembly mimics. PNAS 2006; 103: 17753-8.
130. Benseny-Cases N, Cocera M, Cladera J. Conversion of non-fibrillar [beta]-sheet oligomers into amyloid fibrils in Alzheimer's disease amyloid peptide aggregation. Biochem Biophys Res Commun 2007; 361: 916-21.
131. Hall CK, Wagoner VA. Computational approaches to fibril structure and formation. In: ed.^eds., Methods in Enzymology. Academic Press 2006; pp. 338-65.
132. Kawasaki T, Kamijo S. Inhibition of Aggregation of Amyloid beta42 by Arginine-Containing Small Compounds. Biosci Biotechnol Biochem 2012.
133. Orlando RA, Gonzales AM, Royer RE, Deck LM, Vander Jagt DL. A chemical analog of curcumin as an improved inhibitor of amyloid abeta oligomerization. PLoS One 2012; 7: e31869.
134. Bose PP, Chatterjee U, Xie L, Johansson J, Gothelid E, Arvidsson PI. Effects of Congo Red on A beta(1-40) Fibril Formation Process and Morphology. Acs Chem Neurosci 2010; 1: 315-24.
135. Gellermann GP, Ullrich K, Tannert A, et al. Alzheimer-like plaque formation by human macrophages is reduced by fibrillation inhibitors and lovastatin. J Mol Biol 2006; 360: 251-7.
136. Crowther DC, Kinghorn KJ, Miranda E, et al. Intraneuronal A beta, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer's disease. Neuroscience 2005; 132: 123-35.
137. Stains CI, Mondal K, Ghosh I. Molecules that target beta-amyloid. ChemMedChem 2007; 2: 1674-92.
138. Rizzo S, Riviere C, Piazzi L, et al. Benzofuran-based hybrid compound's for the inhibition of cholinesterase activity, beta amyloid aggregation, and A beta neurotoxicity. J Med Chem 2008; 51: 2883-6.
139. LeVine H, Lampe L, Abdelmoti L, Augelli-Szafran CE. Dihydroxybenzoic Acid Isomers Differentially Dissociate Soluble Biotinyl-A beta(1-42) Oligomers. Biochemistry 2012; 51: 307-15.
140. De Felice FG, Houzel JC, Garcia-Abreu J, et al. Inhibition of Alzheimer's disease beta-amyloid aggregation, neurotoxicity, and in vivo deposition by nitrophenols: implications for Alzheimer's therapy. Faseb J 2001; 15: 1297-9.
141. Lenhart JA, Ling XA, Gandhi R, et al. Clicked Bivalent Ligands Containing Curcumin and Cholesterol As Multifunctional A beta Oligomerization Inhibitors: Design, Synthesis, and Biological Characterization. J Med Chem 2010; 53: 6198-209.
142. Howlett DR, Perry AE, Godfrey F, et al. Inhibition of fibril formation in beta-amyloid peptide by a novel series of benzofurans. Biochem J 1999; 340: 283-9.
143. Tomiyama T, Asano S, Suwa Y, et al. Rifampicin Prevents the Aggregation and Neurotoxicity of Amyloid-Beta Protein in-Vitro. Biochemical and Biophysical Res Communications 1994; 204: 76-83.
144. Cohen T, Frydman-Marom A, Rechter M, Gazit E. Inhibition of amyloid fibril formation and cytotoxicity by hydroxyindole derivatives. Biochemistry 2006; 45: 4727-35.
145. Zhou Y, Jiang C, Zhang Y, et al. Structural optimization and biological evaluation of substituted bisphenol A derivatives as betaamyloid peptide aggregation inhibitors. J Med Chem 2010; 53: 5449-66.
146. Vitiello G, Grimaldi M, D'Ursi AM, D'Errico G. The iAbeta5p beta-breaker peptide regulates the Abeta(25-35) interaction with lipid bilayers through a cholesterol-mediated mechanism. Biochem Biophys Res Commun 2012; 417: 88-92.
147. Giordano C, Sansone A, Masi A, et al. Inhibition of amyloid peptide fragment Abeta25-35 fibrillogenesis and toxicity by Nterminal beta-amino acid-containing esapeptides: is taurine moiety essential for in vivo effects? Chem Biol Drug Des 2012; 79: 30-7.
148. Frydman-Marom A, Shaltiel-Karyo R, Moshe S, Gazit E. The generic amyloid formation inhibition effect of a designed small aromatic beta-breaking peptide. Amyloid 2011; 18: 119-27.
149. Hatip FF, Suenaga M, Yamada T, Matsunaga Y. Reversal of temperature-induced conformational changes in the amyloid-beta peptide, Abeta40, by the beta-sheet breaker peptides 16-23 and 17-24. Br J Pharmacol 2009; 158: 1165-72.
150. De Bona P, Giuffrida ML, Caraci F, et al. Design and synthesis of new trehalose-conjugated pentapeptides as inhibitors of Abeta(1-42) fibrillogenesis and toxicity. J Pept Sci 2009; 15: 220-8.
151. Matharu B, El-Agnaf O, Razvi A, Austen BM. Development of retro-inverso peptides as anti-aggregation drugs for beta-amyloid in Alzheimer's disease. Peptides 2010; 31: 1866-72.
152. Findeis MA, Musso GM, Arico-Muendel CC, et al. Modifiedpeptide inhibitors of amyloid beta-peptide polymerization. Biochemistry 1999; 38: 6791-800.
153. Evans CG, Wisen S, Gestwicki JE. Heat shock proteins 70 and 90 inhibit early stages of amyloid beta-(1-42) aggregation in vitro. J Biol Chem 2006; 281: 33182-91.
154. Smith TJ, Stains CI, Meyer SC, Ghosh I. Inhibition of beta-amyloid fibrillization by directed evolution of a beta-sheet presenting miniature protein. J Am Chem Soc 2006; 128: 14456-7.
155. Chalifour RJ, McLaughlin RW, Lavoie L, et al. Stereoselective interactions of peptide inhibitors with the beta-amyloid peptide. J Biol Chem 2003; 278: 34874-81.
156. Santhoshkumar P, Sharma KK. Inhibition of amyloid fibrillogenesis and toxicity by a peptide chaperone. Mol Cell Biochem 2004; 267: 147-55.
157. Trouw LA, Nielsen HM, Minthon L, et al. C4b-binding protein in Alzheimer's disease: binding to Abeta1-42 and to dead cells. Mol Immunol 2008; 45: 3649-60.
158. Deane R, Singh I, Sagare AP, et al. A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 2012; 122: 1377-92.
159. Turner RT, 3rd, Koelsch G, Hong L, et al. Subsite specificity of memapsin 2 (beta-secretase): implications for inhibitor design. Biochemistry 2001; 40: 10001-6.
160. Hook G, Hook V, Kindy M. The cysteine protease inhibitor, E64d, reduces brain amyloid-beta and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, beta-secretase activity. J Alzheimers Dis 2011; 26: 387-408.